Dexmedetomidine and clonidine inhibit the function of Na(v)1.7 independent of α(2)-adrenoceptor in adrenal chromaffin cells

J Anesth. 2011 Aug;25(4):549-57. doi: 10.1007/s00540-011-1168-6. Epub 2011 May 24.

Abstract

Purpose: Besides being administered systemically for sedation and analgesia, α(2)-agonists such as dexmedetomidine and clonidine have been administered with intrathecal, epidural, or perineural injections, leading to an antinociceptive effect at the spinal cord or peripheral nerve level. However, the mechanism for this remains unclear. In the present study, we examined whether dexmedetomidine and clonidine could inhibit the function of tetrodotoxin-sensitive Na(+) channels, which play important roles in the generation of pain.

Methods: Cultured bovine adrenal chromaffin cells expressing the tetrodotoxin-sensitive Na(v)1.7 Na(+) channel isoform were incubated in KRP buffer containing 2 μCi (22)NaCl for 5 min without or with dexmedetomidine or clonidine in the absence or presence of veratridine, α-scorpion venom, β-scorpion venom, Ptychodiscus brevis toxin-3 or ouabain. Cells were then washed and counted radioactively.

Results: Dexmedetomidine and clonidine reduced veratridine-induced (22)Na(+) influx via Na(v)1.7 in a concentration-dependent manner (EC(50) = 50 μM and 530 μM), even in the presence of ouabain, an inhibitor of Na(+), K(+)-ATPase. Dexmedetomidine and clonidine shifted the concentration-response curve of veratridine for (22)Na(+) influx downward without altering the EC(50) of veratridine. Atipamezole and yohimbine, α(2)-antagonists, did not prevent the inhibition of veratridine-induced (22)Na(+) influx by dexmedetomidine. Dexmedetomidine and clonidine combined with lidocaine induced more inhibition of veratridine-induced (22)Na(+) influx than each drug did individually. Atipamezole and yohimbine did not prevent the lidocaine-enhancing effect of dexmedetomidine and clonidine.

Conclusion: Dexmedetomidine and clonidine inhibit the function of Na(v)1.7 independent of α(2)-adrenoceptor. These results may lead to a deeper understanding of the peripheral antinociceptive effects of α (2)-agonists.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-2 Receptor Agonists / pharmacology*
  • Adrenergic alpha-2 Receptor Antagonists / pharmacology
  • Animals
  • Binding Sites
  • Cattle
  • Cells, Cultured
  • Chromaffin Cells / drug effects*
  • Chromaffin Cells / metabolism
  • Clonidine / pharmacology*
  • Cyclopentanes / pharmacology
  • Dexmedetomidine / pharmacology*
  • Imidazoles / pharmacology
  • Lidocaine / pharmacology
  • Organophosphorus Compounds / pharmacology
  • Ouabain / pharmacology
  • Pain / physiopathology
  • Receptors, Adrenergic, alpha-2 / metabolism*
  • Scorpion Venoms / pharmacology
  • Sodium / metabolism
  • Sodium Channels / metabolism*
  • Tetrodotoxin / pharmacology
  • Veratridine / pharmacology
  • Yohimbine / pharmacology

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Cyclopentanes
  • Imidazoles
  • O,O-diphenyl-N-cyclopentylphosphoramidate
  • Organophosphorus Compounds
  • Receptors, Adrenergic, alpha-2
  • Scorpion Venoms
  • Sodium Channels
  • atipamezole
  • Yohimbine
  • Tetrodotoxin
  • Ouabain
  • Dexmedetomidine
  • Veratridine
  • Lidocaine
  • Sodium
  • Clonidine